Submissions

Browse Submissions

Filter Results

CHPA looks forward to working closely with FDA and other key stakeholders throughout the OMUFA reauthorization process as we work together to ensure the continued success of FDA’s OTC monograph program.

Oct 27, 2023

Pursuant to 16 C.F.R. § 1.31, through this petition, Petitioners respectfully request that FTC withdraw the notice of penalty offenses that were sent to nearly 700 companies.

Sep 15, 2023

CHPA strongly urges the Food and Drug Administration to deny the petition to repeal 21 CFR 73.575, which permits the use of TiO2 in food and dietary supplements. Based on extensive scientific research and regulatory evaluations, TiO2 is deemed safe for use as a food additive when consumed within established regulatory limits.

Aug 29, 2023

CHPA thanks FDA for providing a process to give feedback from industry leveraging science and risk-based approaches to appropriately identify, assess and control (where needed) NDSRIs and preventing unacceptable levels of nitrosamines in drug products.

Jul 3, 2023

Industry appreciates this guidance to enable the assembly of suitable and successful OMORs. FDA must adopt standards and expectations consistent with the intent of OMUFA, rather than the NDA paradigm, with which it is very familiar.

Jun 12, 2023

CHPA appreciates this opportunity to comment on the Synthetic Dye Petition submitted to the California Department of Public Health requesting that a warning be placed on food and dietary supplement products related to adverse neurobehavioral effects purportedly associated with ingestion of synthetic food dyes.

May 12, 2023

Filter Results